Ringer lactate similar to standard salt solution

Article

Ringer lactate has a similar effect to a fortified balanced salt solution on corneal endothelial cell loss after phacoemulsification.

Ringer lactate similar to standard salt solution

Ringer lactate has a similar effect to a fortified balanced salt solution on corneal endothelial cell loss after phacoemulsification.

A team led by Dr Barun K. Nayak, Hinduja Hospital, Veer Sawarkar Marg, Mahim, Mumbai, India, conducted a prospective randomized controlled double-blinded clinical study on 75 eyes of 75 patients with senile cataract up to nuclear grade III. All patients were randomized to receive a fortified balanced salt solution (Group A) or Ringer lactate (Group B) as an intraocular irrigating solution.

Corneal endothelial cell density was the primary outcome and pachymetry was recorded preoperatively and one week and one and six months after treatment.

The results revealed no significant difference in postoperative percentage of endothelial cell loss between the two groups at one week, one month and 6 month follow-ups.

Postoperative percentage change in pachymetry was not significant between the two groups at the one week or one month follow-ups but there was a significant difference at the six-month follow-up.

The abstract was published in the Journal of Cataract and Refractive Surgery .

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.